(1) Background: Since its discovery, COVID-19 has caused more than 256 million cases,
with a cumulative death toll of more than 5.1 million, worldwide. Early identification of …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led
to an unprecedented global healthcare crisis. While SARS-CoV-2-associated COVID-19 …

Objective: Understanding the minimum infective dose is significant for risk assessment in the
performance of suitable infection control strategies in healthcare centers. However, the …

Currently, biological markers for COVID-19 disease severity still constitute the main goal of
enhancing an efficient treatment to reduce critical consequences such as an abnormal …

Introduction and objectives In patients with coronavirus disease 2019 (COVID-19), several
abnormal hematological biomarkers have been reported. The current study aimed to find out …

Background SARS-CoV-2 infection is a risk factor for the development of depressive
symptoms such as lack of energy, loss of interest, and depressed mood. Inflammatory …

With the end of the pandemic, COVID-19 has entered an endemic phase with expected
seasonal spikes. Consequently, the implementation of easily accessible prognostic …

C-reactive protein (CRP) is an important part of the immune system's reaction to various
pathological impulses such as bacterial infections, systemic inflammation, and internal …

Rationale Abnormal values of hypercoagulability biomarkers, such as D-dimer, have been
described in Coronavirus Disease 2019 (COVID-19), which has also been associated with …

Introduction COVID-19 is associated to an increased risk of thrombosis, as a result of a
complex process that involves the activation of vascular and circulating cells, the release of …